Dr. Anne Moore, MD

Dr. Moore practices at Columbia University Irving Medical Center in New York, New York.

Dr. Moore's NPI, 1639266703, was assigned on October 9, 2006. Dr. Moore graduated from Vagelos College of Physicians and Surgeons in 1969. Dr. Moore holds New York license 112094.

Dr. Moore's primary practice is Columbia University Irving Medical Center, at 622 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 305-4920.

Dr. Moore's primary practice is Columbia University Irving Medical Center in New York, New York. The medical group on file is Weill Cornell Physicians. Dmand AI also links Dr. Moore to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Moore practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Moore's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Moore is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Moore's licenses on file in 5 states: New York, Colorado, Minnesota, Oregon and North Carolina.

Dmand AI lists breast cancer, lung cancer, lymphedema and lymphoma among the conditions Dr. Moore treats.

CMS data shows 733 Medicare services from Dr. Moore across 4 procedure codes in 2024, for 611 Medicare patients. Medicare paid $77,469 for them. Every service was in an office.

CMS counts 611 Medicare patients who saw Dr. Moore in 2024. The largest group is 75 to 84, with 318 patients. 75% of them have cancer, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 0.98, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Moore's median patient age at 70, with 96% women.

In 2024, Dr. Moore wrote 179 Medicare Part D claims for 75 patients. 94% of them were for generic drugs. CMS names the drug for 146 of them, across 4 drugs with 11 or more claims each, at $4,976 in total drug cost. In 2023, CMS named 171 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Moore for performance year 2024, reported through an alternative payment model (APM).

Dmand AI links 31 papers to Dr. Moore, published from 2007 to 2022. 2021 was the busiest year, with 3. The most frequent topics are Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Biomarkers, Tumor. Dr. Moore has published most often in Breast Cancer Res Treat. Dr. Moore's most frequent co-authors are Tessa Cigler, MD, Linda T. Vahdat, MD and Ellen Chuang, MD.

CMS Open Payments shows 11 general payments to Dr. Moore from 8 drug and device companies from 2017 to 2021. Food and beverage make up the largest share, 95% of the total. Amgen Inc. paid the most, $93.

Dmand AI lists 3 awards for Dr. Moore, most recently CMS Stage 1 EHR in 2013.

Dr. Moore graduated from Vagelos College of Physicians and Surgeons in 1969. Dr. Moore is a member of ASCO.

Dr. Moore is in network with 15 carriers, including Elevance, Aetna and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.